カテゴリ： GlobalData, イギリス, 企業調査

Mylan NV (MYL)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Mylan NV (MYL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012229
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：183
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines and consumer healthcare products. It offers pharmaceutical products in multiple forms across therapeutic categories such as respiratory and allergy, cardiovascular, central nervous systems, infectious disease, oncology, anesthesia and others. Mylan sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company has research and development facilities in the US, Canada, the UK, Ireland, Italy, Germany, India and Japan. Mylan is headquartered in Hatfield, Hertfordshire, the UK.

Mylan NV (MYL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Mylan NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 12
Mylan NV, Medical Devices Deals, 2011 to YTD 2017 14
Mylan NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Mylan NV, Pharmaceuticals & Healthcare, Deal Details 20
Asset Purchase 20
Mylan Acquires Global Rights to Cold-EEZE Brand from ProPhase Labs 20
Mylan Acquires Topical Pharmaceutical Business of Renaissance for up to USD1 Billion 21
Teva Pharma May Divest its Assets 22
Mylan Acquires Female Health Care Businesses from Famy Care for USD800 Million 24
Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 26
Mylan to Acquire Rights to Arixtra Injection from Aspen Global 28
Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 29
Mylan Completes Acquisition Of Drug Manufacturing Plant From Unichem For US$30 Million 30
Rottapharm|Madaus Acquires Zyma Brands 31
Meda Acquires OTC Sleep Aid Product, MidNite 32
Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For US$33 Million 33
Meda Completes Acquisition Of Women’s Health Business From Jazz Pharma For US$95 Million 34
Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 36
Mylan Completes Acquisition Of Respiratory Delivery Platform From Pfizer For US$348 Million 37
Meda Acquires Rights to Three Nordic OTC Drugs from McNeil and Cilag for USD111 Million 39
Meda Completes Acquisition Of Global Rights To Elidel From Novartis For US$420 Million 40
Meda Acquires Two Additional OTC Products In US From GlaxoSmithKline 42
Private Equity 43
Riverside Acquires Euromed from Meda for USD86.7 Million 43
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 44
Partnerships 46
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 46
Unimedic Enters into Distribution Agreement with Mylan 47
Mabion Enters into Distribution Agreement with Mylan 48
Pulmatrix Enters into Co-Development Agreement with Mylan 49
AB-Biotics Enters into Distribution Agreement with Mylan 50
Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 51
Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 52
Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 53
Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 54
Venus Pharma Enters Into Co-Marketing Agreement With Mylan For Meropenem 56
Meda Expands Co-Development Agreement With Cipla For Dymista 57
Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 58
Agila Specialties Forms Joint Venture With Jamp Pharma 59
Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 60
Matrix Labs Plans Co-Marketing Agreement For 100 Products 61
Bristol-Myers Squibb Enters Into Co-Marketing Agreement With Matrix Labs 62
Licensing Agreements 63
Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 63
Mylan Enters into Licensing Agreement with Genentech and Roche 64
Mylan Enters into Licensing Agreement with Medicines Patent Pool 65
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 66
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 67
Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 68
Gilead Sciences Expands Licensing Agreement with Mylan Labs 70
Mylan Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 71
Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 72
Gilead Sciences Expands Licensing Agreement with Mylan Labs 73
Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 74
Venus Pharma Enters into Licensing Agreement with Mylan for Meropenem 75
Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 76
Mylan Enters Into Licensing Agreement With Orion for Stalevo 77
Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 78
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 79
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 81
Moberg Pharma Amends Licensing Agreement with Meda 82
Meda Enters Into Licensing Agreement With Moberg Derma For Nalox 83
Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 84
Valeant Pharma Enters Into Licensing Agreement With Meda For Elidel And Xerese 86
Meda Amends Licensing Agreement With Medivir For Xerese 88
Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 89
Equity Offering 91
Abbott Sells stock of Mylan for USD2.29 Billion 91
Meda to Raise USD278.7 Million in Rights Offering 92
Rottapharm Withdraws IPO for USD614.7 Million 94
Debt Offering 95
Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 95
Mylan Raises USD796 Million in Private Placement of 1.25% Notes Due 2020 96
Mylan Raises USD796 Million in Private Placement of 3.125% Notes Due 2028 97
Mylan Raises USD531 Million in Private Placement of Floating Rate Notes Due 2018 98
Mylan Raises USD1.06 Billion in Private Placement of 2.25% Notes Due 2024 99
Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 100
Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 101
Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 102
Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 103
Mylan Raises USD500 Million in Private Placement 3.75% Notes Due 2020 104
Mylan Raises USD500 Million in Private Placement 3% Notes Due 2018 105
Mylan Completes Public Offering Of Notes Due 2043 For US$500 Million 106
Mylan Completes Public Offering Of Notes Due 2016 For US$500 Million 108
Mylan Completes Public Offering Of Notes Due 2023 For US$500 Million 110
Mylan Completes Public Offering Of Notes Due 2019 For US$500 Million 112
Mylan Completes Private Placement Of Notes Due 2018 For US$650 Million 113
Mylan Completes Private Placement Of Notes Due 2016 For US$500 Million 114
Meda Prices Public Offering Of Notes Due 2016 For US$62 Million 115
Meda Prices Public Offering Of Notes Due 2018 For US$92.4 Million 116
Mylan Completes Private Placement Of Notes Due 2023 For US$750 Million 117
Acquisition 118
Mylan Acquires Meda for USD9.9 Billion 118
Teva Pharma, Mylan May Acquire Teut|Pfizer 120
Meda Acquires Rottapharm from Fidim for USD3 Billion 122
Fidim Acquires Rottapharm Biotech from Rottapharm 123
Meda Acquires ZpearPoint, Dental Products Provider 124
Mylan Completes Acquisition Of Agila Specialties From Strides Arcolab For Up To US$1.75 Billion 125
Mylan Rumored To Acquire Bafna Pharma 128
Meda Completes Acquisition Of Acton Pharma For Up To US$200 Million 129
Mylan Acquires Synerx Pharma, Generic Maker 131
Meda Completes Acquisition Of Antula From Healthcare Brands 132
Mylan NV – Key Competitors 133
Mylan NV – Key Employees 134
Mylan NV – Locations And Subsidiaries 135
Head Office 135
Other Locations & Subsidiaries 135
Recent Developments 142
Financial Announcements 142
Nov 06, 2017: Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance 142
Aug 09, 2017: Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance 144
May 10, 2017: Mylan Reports First Quarter 2017 Results 148
Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 150
Nov 09, 2016: Mylan Reports Third Quarter 2016 Results 152
Aug 09, 2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8% 156
May 03, 2016: Mylan Reports Strong First Quarter 2016 Earnings Results Including Total Revenues Up 17% 159
Feb 10, 2016: Mylan Full Year Adjusted Diluted EPS Up 21% to $4.30 161
Corporate Communications 165
Nov 10, 2017: Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange 165
Sep 13, 2017: Mylan Names Dennis Zeleny as Chief Human Relations Officer 166
May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 167
Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 168
Dec 20, 2016: Mylan launches authorised generic version of EpiPen 169
Jun 23, 2016: Mylan Donates €1 Million to the Princess Máxima Center for Pediatric Oncology 170
May 03, 2016: Mylan Names Kenneth Parks Chief Financial Officer 171
Feb 22, 2016: Mylan Appoints Anthony Mauro Chief Commercial Officer 172
Feb 22, 2016: Mylan CEO Heather Bresch Elected Chair of Generic Pharmaceutical Association 173
Jan 08, 2016: Mylan CFO John Sheehan to Retire as of April 1, 2016 174
Legal and Regulatory 175
Nov 06, 2017: Phosphagenics Mylan Arbitration Hearing Concluded 175
Oct 31, 2017: Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint 176
Aug 25, 2016: Teva Plunges After Two U.S. Copaxone Patents Invalidated 177
Product News 179
Nov 29, 2016: New ADEKplus a Fat Soluble Nutritional Product Launched to Aid Conditions Such as Cystic Fibrosis 179
09/14/2017: Mylan Expands Womens Healthcare Portfolio with Launch of Generic Minastrin 24 FE Tablets 180
Product Approvals 181
Jan 11, 2016: Mylan Confirms FDA Submission of ANDA for Generic Advair Diskus 181
Other Significant Developments 182
Mar 08, 2016: Mylan Health Hackathon to Focus on Delivering Better Health for a Better World 182
Appendix 183
Methodology 183
About GlobalData 183
Contact Us 183
Disclaimer 183

List of Tables
Mylan NV, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Mylan NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Mylan NV, Deals By Therapy Area, 2011 to YTD 2017 12
Mylan NV, Medical Devices Deals, 2011 to YTD 2017 14
Mylan NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Mylan Acquires Global Rights to Cold-EEZE Brand from ProPhase Labs 20
Mylan Acquires Topical Pharmaceutical Business of Renaissance for up to USD1 Billion 21
Teva Pharma May Divest its Assets 22
Mylan Acquires Female Health Care Businesses from Famy Care for USD800 Million 24
Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 26
Mylan to Acquire Rights to Arixtra Injection from Aspen Global 28
Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 29
Mylan Completes Acquisition Of Drug Manufacturing Plant From Unichem For US$30 Million 30
Rottapharm|Madaus Acquires Zyma Brands 31
Meda Acquires OTC Sleep Aid Product, MidNite 32
Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For US$33 Million 33
Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For US$95 Million 34
Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 36
Mylan Completes Acquisition Of Respiratory Delivery Platform From Pfizer For US$348 Million 37
Meda Acquires Rights to Three Nordic OTC Drugs from McNeil and Cilag for USD111 Million 39
Meda Completes Acquisition Of Global Rights To Elidel From Novartis For US$420 Million 40
Meda Acquires Two Additional OTC Products In US From GlaxoSmithKline 42
Riverside Acquires Euromed from Meda for USD86.7 Million 43
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 44
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 46
Unimedic Enters into Distribution Agreement with Mylan 47
Mabion Enters into Distribution Agreement with Mylan 48
Pulmatrix Enters into Co-Development Agreement with Mylan 49
AB-Biotics Enters into Distribution Agreement with Mylan 50
Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 51
Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 52
Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 53
Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 54
Venus Pharma Enters Into Co-Marketing Agreement With Mylan For Meropenem 56
Meda Expands Co-Development Agreement With Cipla For Dymista 57
Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 58
Agila Specialties Forms Joint Venture With Jamp Pharma 59
Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 60
Matrix Labs Plans Co-Marketing Agreement For 100 Products 61
Bristol-Myers Squibb Enters Into Co-Marketing Agreement With Matrix Labs 62
Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 63
Mylan Enters into Licensing Agreement with Genentech and Roche 64
Mylan Enters into Licensing Agreement with Medicines Patent Pool 65
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 66
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 67
Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 68
Gilead Sciences Expands Licensing Agreement with Mylan Labs 70
Mylan Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 71
Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 72
Gilead Sciences Expands Licensing Agreement with Mylan Labs 73
Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 74
Venus Pharma Enters into Licensing Agreement with Mylan for Meropenem 75
Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 76
Mylan Enters Into Licensing Agreement With Orion for Stalevo 77
Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 78
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 79
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 81
Moberg Pharma Amends Licensing Agreement with Meda 82
Meda Enters Into Licensing Agreement With Moberg Derma For Nalox 83
Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 84
Valeant Pharma Enters Into Licensing Agreement With Meda For Elidel And Xerese 86
Meda Amends Licensing Agreement With Medivir For Xerese 88
Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 89
Abbott Sells stock of Mylan for USD2.29 Billion 91
Meda to Raise USD278.7 Million in Rights Offering 92
Rottapharm Withdraws IPO for USD614.7 Million 94
Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 95
Mylan Raises USD796 Million in Private Placement of 1.25% Notes Due 2020 96
Mylan Raises USD796 Million in Private Placement of 3.125% Notes Due 2028 97
Mylan Raises USD531 Million in Private Placement of Floating Rate Notes Due 2018 98
Mylan Raises USD1.06 Billion in Private Placement of 2.25% Notes Due 2024 99
Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 100
Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 101
Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 102
Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 103
Mylan Raises USD500 Million in Private Placement 3.75% Notes Due 2020 104
Mylan Raises USD500 Million in Private Placement 3% Notes Due 2018 105
Mylan Completes Public Offering Of Notes Due 2043 For US$500 Million 106
Mylan Completes Public Offering Of Notes Due 2016 For US$500 Million 108
Mylan Completes Public Offering Of Notes Due 2023 For US$500 Million 110
Mylan Completes Public Offering Of Notes Due 2019 For US$500 Million 112
Mylan Completes Private Placement Of Notes Due 2018 For US$650 Million 113
Mylan Completes Private Placement Of Notes Due 2016 For US$500 Million 114
Meda Prices Public Offering Of Notes Due 2016 For US$62 Million 115
Meda Prices Public Offering Of Notes Due 2018 For US$92.4 Million 116
Mylan Completes Private Placement Of Notes Due 2023 For US$750 Million 117
Mylan Acquires Meda for USD9.9 Billion 118
Teva Pharma, Mylan May Acquire Teut|Pfizer 120
Meda Acquires Rottapharm from Fidim for USD3 Billion 122
Fidim Acquires Rottapharm Biotech from Rottapharm 123
Meda Acquires ZpearPoint, Dental Products Provider 124
Mylan Completes Acquisition Of Agila Specialties From Strides Arcolab For Up To US$1.75 Billion 125
Mylan Rumored To Acquire Bafna Pharma 128
Meda Completes Acquisition Of Acton Pharma For Up To US$200 Million 129
Mylan Acquires Synerx Pharma, Generic Maker 131
Meda Completes Acquisition Of Antula From Healthcare Brands 132
Mylan NV, Key Competitors 133
Mylan NV, Key Employees 134
Mylan NV, Other Locations 135
Mylan NV, Subsidiaries 136

★海外企業調査レポート[Mylan NV (MYL)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Southern Minnesota Municipal Power Agency：企業の発電所・SWOT分析2018
    Southern Minnesota Municipal Power Agency - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, inform …
  • Bacardi Limited：企業の戦略・SWOT・財務情報
    Bacardi Limited - Strategy, SWOT and Corporate Finance Report Summary Bacardi Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Skanska AB：企業の戦略・SWOT・財務分析
    Skanska AB - Strategy, SWOT and Corporate Finance Report Summary Skanska AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Healthsense Inc-医療機器分野：企業M&A・提携分析
    Summary Healthsense Inc (Healthsense), a subsidiary of GreatCall Inc is a medical device company that provides remote monitoring services. The company offers technology-enabled care solutions, aging technology services, for the entire senior care continuum. Its products include eNeighbor remote moni …
  • Solvay Group：企業のM&A・事業提携・投資動向
    Solvay Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Solvay Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Uni-President China Holdings Ltd.：戦略・SWOT・企業財務分析
    Uni-President China Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary Uni-President China Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Aristocrat Leisure Ltd (ALL)：企業の財務・戦略的SWOT分析
    Aristocrat Leisure Ltd (ALL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Vectra Bank Colorado：企業の戦略・SWOT・財務情報
    Vectra Bank Colorado - Strategy, SWOT and Corporate Finance Report Summary Vectra Bank Colorado - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Itau Unibanco Holding SA：企業のM&A・事業提携・投資動向
    Itau Unibanco Holding SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Itau Unibanco Holding SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • IQVIA Holdings Inc (IQV)：企業の財務・戦略的SWOT分析
    IQVIA Holdings Inc (IQV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Natrix Separations Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Natrix Separations Inc (Natrix), formerly Nysa Membrane Technologies, a subsidiary of Merck KGaA, is a supplier of single use and multi-cycle disposable chromatography products. The company offers NatriFlo HD-Q membrane adsorbers, an advanced material with a three-dimensional macroporous hyd …
  • Sandvik AB：企業の戦略・SWOT・財務情報
    Sandvik AB - Strategy, SWOT and Corporate Finance Report Summary Sandvik AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Rolta India Ltd (ROLTA)：企業の財務・戦略的SWOT分析
    Rolta India Ltd (ROLTA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Pharco Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Pharco Pharmaceuticals Inc (Pharco Pharmaceuticals), a subsidiary of Pharco Corp, is a manufacturer of branded and generic pharmaceutical products. The company offers products such as alambupine, alfatral, amlodipine, amrase, amrizole, bisadyl, bromhexine, carbolase, ciprofloxacin, dexametha …
  • Huttig Building Products Inc：企業の戦略・SWOT・財務情報
    Huttig Building Products Inc - Strategy, SWOT and Corporate Finance Report Summary Huttig Building Products Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Dow Jones & Co Inc：企業の戦略的SWOT分析
    Dow Jones & Co Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Cosmo Pharmaceuticals NV (COPN)-医療機器分野：企業M&A・提携分析
    Summary Cosmo Pharmaceuticals NV (Cosmo) is a pharmaceutical company that develops drugs for the treatment of gastro-intestinal diseases. The company develops its pharmaceutical products based on its multi matrix (MMX) technology. Its proprietary clinical development pipeline intended for the treatm …
  • Zeria Pharmaceutical Co Ltd (4559)：企業の財務・戦略的SWOT分析
    Summary Zeria Pharmaceutical Co Ltd (Zeria), formerly Zeria Yakusho Kenkyusho Co Ltd is a pharmaceutical company that manufactures pharmaceutical and non-pharmaceuticals, veterinary pharmaceuticals, industrial chemicals and reagents. The company imports and exports healthcare products such as cosmet …
  • Erbud SA：企業の戦略・SWOT・財務情報
    Erbud SA - Strategy, SWOT and Corporate Finance Report Summary Erbud SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • GAMCO Investors, Inc.：企業の戦略・SWOT・財務情報
    GAMCO Investors, Inc. - Strategy, SWOT and Corporate Finance Report Summary GAMCO Investors, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆